The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
International tailored chemotherapy adjuvant trial: ITACA trial.
S. Novello
No relevant relationships to disclose
G. Scagliotti
Honoraria - AstraZeneca; Lilly; Roche
V. Torri
No relevant relationships to disclose
V. Monica
No relevant relationships to disclose
M. Papotti
Honoraria - Lilly
C. Grohe
No relevant relationships to disclose
G. Valmadre
No relevant relationships to disclose
E. Bria
No relevant relationships to disclose
I. Colantonio
No relevant relationships to disclose
M. H. Serke
Consultant or Advisory Role - Lilly
Honoraria - Lilly
E. Stoelben
No relevant relationships to disclose
M. Geissler
No relevant relationships to disclose
M. Schena
No relevant relationships to disclose
A. Santo
No relevant relationships to disclose
O. Alabiso
No relevant relationships to disclose
C. Schumann
No relevant relationships to disclose
C. Manegold
Honoraria - Lilly